• Source:JND
Add as a preferred

Natco Pharma Share Price Today: Shares of Natco Pharma Ltd on Thursday fell 20 per cent after it reported a 37.75 per cent decline in consolidated net profit for the December quarter. The stock fell 19.86 per cent to Rs 975 on the BSE. On the NSE, it fell 19.99 per cent to Rs 975.05.

Natco Pharma Ltd on Wednesday reported that its consolidated net profit declined 37.75 per cent to Rs 132.4 crore in the December quarter due to a decline in exports of formulations.

Natco Pharma said in a regulatory filing that the company had posted a consolidated net profit of Rs 212.7 crore in the third quarter of the previous fiscal.

It said consolidated income from operations stood at Rs 474.8 crore in the quarter under review as against Rs 758.6 crore in the same period last year.

Formulation exports declined to Rs 285.8 crore in the third quarter as against Rs 605.6 crore in the same period last fiscal. In a presentation to investors, Natco Pharma said its formulation sales in the domestic market stood at Rs 96.1 crore as against Rs 99.4 crore in the same period last year.

Also Read: Gold Rate Today In Chennai, Hyderabad, Patna, Kolkata, Mumbai And Other Cities; Check Latest 22K/24K Prices

Natco Pharma Q3 Result

Natco Pharma's performance declined sharply in Q3 FY25. Its revenues fell to Rs 474.8 crore, reflecting a 37.41% decline over the previous year, and its net profit also fell by 37.47% to Rs 132.4 crore. The decline in revenues and profits was even more severe on a quarterly basis: revenues fell by 65.37% and profits fell by 80.36%.

On the other hand, its operational efficiency, as evidenced by a 2,717-basis-point contraction in EBITDA margin, fell to just 8.2% from 35.3% in the same quarter last year.

The increase in selling, general and administrative expenses rose by 16.16% year-on-year, putting further pressure on profitability. The stock, which gained 11.74% in the past week, is in the red after falling 18.5% in trading on February 13 as investors were disappointed.

The stock has done well in the short term over the past week, but gains have fallen -8.4% in the past six months and the year-to-date performance has been -4.89%, weighed down by broader concerns about the company's financial health and operational struggles.

Also Read: Hexawave Technologies IPO Day 2: Check Subscription Status, Latest GMP, And Other Details

(With Inputs From PTI)